The natural carotenoid astaxanthin, a PPAR-α agonist and PPAR-γ antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes

Molecular Nutrition and Food Research

Volumn 56, Issue 6, 2012, Pages 878-888

  Jia, Yaoyao ^a   Kim, Jin Young ^a   Jun, Hee Jin ^a   Kim, Sun Joong ^a   Lee, Ji Hae ^a   Hoang, Minh Hien ^a   Hwang, Kwang Yeon ^a   Um, Soo Jong ^b   Chang, Hyo Ihl ^a   Lee, Sung Joon ^a  

^a Korea University   (South Korea)

^b Sejong University   (South Korea)

Author keywords

Astaxanthin; Lipid metabolism; PPAR; Seafood; Transcriptome

Indexed keywords

ANTIOXIDANT; ASTAXANTHIN; LIPOTROPIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; XANTHOPHYLL;

ANIMAL; ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CHO CELL; CRICETULUS; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION PROFILING; GENETICS; HAMSTER; HUMAN; LIPID METABOLISM; LIVER CELL; METABOLISM; REPORTER GENE; SURFACE PLASMON RESONANCE; TRANSCRIPTION INITIATION;

ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION PROFILING; GENES, REPORTER; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPID METABOLISM; LIPOTROPIC AGENTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR ALPHA; PPAR GAMMA; SURFACE PLASMON RESONANCE; TRANSCRIPTIONAL ACTIVATION; XANTHOPHYLLS;

EID: 84862575244     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100798     Document Type: Article

References (43)

1. Bensinger, S. J., Tontonoz, P., Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454, 470-477.
2. Nettles, K. W., Insights into PPAR gamma from structures with endogenous and covalently bound ligands. Nat. Struct. Mol. Biol. 2008, 15, 893-895.
3. van Bilsen, M., van Nieuwenhoven, F. A., PPARs as therapeutic targets in cardiovascular disease. Expert Opin. Ther. Targets 2010, 14, 1029-1045.
4. Robinson, E., Grieve, D. J., Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol. Ther. 2009, 122, 246-263.
5. Pineda Torra, I., Gervois, P., Staels, B., Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 1999, 10, 151-159.
6. McGarry, J. D., Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51, 7-18.
7. Latruffe, N., Vamecq, J., Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie 1997, 79, 81-94.
8. Neve, B. P., Fruchart, J. C., Staels, B., Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Bioche. Pharmacol. 2000, 60, 1245-1250.
9. Barish, G. D., Narkar, V. A., Evans, R. M., PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 2006, 116, 590-597.
10. Cohen, D., FDA puts rosiglitazone post-marketing trial on hold. Br. Med. J. 2010, 341, c4017.
11. Huang, T. H., Teoh, A. W., Lin, B. L., Lin, D. S., et al., The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol. Res. 2009, 60, 195-206.
12. Chinetti-Gbaguidi, G., Fruchart, J. C., Staels, B., Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr. Opin. Pharmacol. 2005, 5, 177-183.
13. Moran-Salvador, E., Lopez-Parra, M., Garcia-Alonso, V., Titos, E., et al., Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J. 2011, 25, 2538-2550.
14. Fassett, R. G., Coombes, J. S., Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol. 2009, 5, 333-342.
15. Fassett, R. G., Coombes, J. S., Astaxanthin: a potential therapeutic agent in cardiovascular disease. Mar. Drugs. 2011, 9, 447-465.
16. Wolf, A. M., Asoh, S., Hiranuma, H., Ohsawa, I., et al., Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J. Nutr. Biochem. 2010, 21, 381-389.
17. Jacobsson, L. S., Yuan, X. M., Zieden, B., Olsson, A. G., Effects of alpha-tocopherol and astaxanthin on LDL oxidation and atherosclerosis in WHHL rabbits. Atherosclerosis 2004, 173, 231-237.
18. Iwamoto, T., Hosoda, K., Hirano, R., Kurata, H., et al., Inhibition of low-density lipoprotein oxidation by astaxanthin. J. Atheroscler. Thromb. 2000, 7, 216-222.
19. Pashkow, F. J., Watumull, D. G., Campbell, C. L., Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am. J. Cardiol. 2008, 101, 58d-68d.
20. Sevilla, M. A., Monroy-Ruiz, J., Carron, R., Montero, M. J., Astaxanthin-enriched-diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats. Pharmacol. Res. 2011, 63, 44-50.
21. Hussein, G., Nakagawa, T., Goto, H., Shimada, Y., et al., Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci. 2007, 80, 522-529.
22. Yang, Y., Seo, J. M., Nguyen, A., Pham, T. X., et al., Astaxanthin-rich extract from the green alga Haematococcus pluvialis lowers plasma lipid concentrations and enhances antioxidant defense in apolipoprotein E knockout mice. J. Nutr. 2011, 141, 1611-1617.
23. Yazawa, K., Ikeuchi, M., Koyama, T., Takahashi, J., Effects of astaxanthin in obese mice fed a high-fat diet. Biosci. Biotechnol. Biochem. 2007, 71, 893-899.
24. Jun, H.-J., Chung, M., Dawson, K., Rodriguez, R., et al., Nutrigenomic analysis of hypolipidemic effects of Agastache rugosa essential oils in HepG2 cells and C57 BL/6 mice. Food Sci. Biotechnol. 2010, 19, 219-227.
25. Jia, Y., Bhuiyan, M. J., Jun, H. J., Lee, J. H., et al., Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism. Bioorg. Med. Chem. Lett. 2011, 21, 5876-5880.
26. Hoang, M. H., Houng, S. J., Jun, H. J., Lee, J. H., et al., Barley intake induces bile acid excretion by reduced expression of intestinal ASBT and NPC1L1 in C57 BL/6 J mice. J. Agric. Food Chem. 2011, 59, 6798-6805.
27. Bhuiyan, M. J., Do, H. V., Mun, S., Jun, H. J., et al., Hypocholesterolemic and hypoglycemic effects of enzymatically modified carbohydrates from rice in high-fat-fed C57 BL/6 J mice. Mol. Nutr. Food. Res. 2011, 55(Suppl 2), S214-S226.
28. Park, H. M., Lee, J. H., Yaoyao, J., Jun, H. J., et al., Limonene, a natural cyclic terpene, is an agonistic ligand for adenosine A(2 A) receptors. Biochem. Biophys. Res. Commun. 2011, 404, 345-348.
29. Staels, B., Rubenstrunk, A., Hanf, R., Hum, D. W., et al., Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta-Mol. Cell Biol. 2007, 1771, 1065-1081.
30. Balakumar, P., Rose, M., Ganti, S. S., Krishan, P., et al., PPAR dual agonists: are they opening Pandora's box? Pharmacol. Res. 2007, 56, 91-98.
31. Fievet, C., Fruchart, J. C., Staels, B., PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 2006, 6, 606-614.
32. Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., et al., Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 2006, 536, 182-191.
33. Zoete, V., Grosdidier, A., Michielin, O., Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta 2007, 1771, 915-925.
34. Xu, H. E., Stanley, T. B., Montana, V. G., Lambert, M. H., et al., Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 2002, 415, 813-817.
35. de Barros, M. P., Otton, R., Marin, D. P., Bolin, A. P., et al., Astaxanthin ameliorates the redox imbalance in lymphocytes of experimental diabetic rats. Chem. Biol. Interact. 2010, 186, 306-315.
36. Yoshida, H., Yanai, H., Ito, K., Tomono, Y., et al., Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis 2010, 209, 520-523.
37. O'Sullivan, L., Ryan, L., O'Brien, N., Comparison of the uptake and secretion of carotene and xanthophyll carotenoids by Caco-2 intestinal cells. Br. J. Nutr. 2007, 98, 38-44.
38. Osterlie, M., Bjerkeng, B., Liaaen-Jensen, S., Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin. J. Nutr. Biochem. 2000, 11, 482-490.
39. Postic, C., Girard, J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 2008, 118, 829-838.
40. Lefebvre, P., Chinetti, G., Fruchart, J. C., Staels, B., Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest. 2006, 116, 571-580.
41. Suzuki, K., Takahashi, K., Nishimaki-Mogami, T., Kagechika, H., et al., Docosahexaenoic acid induces adipose differentiation-related protein through activation of retinoid x receptor in human choriocarcinoma BeWo cells. Biol. Pharm. Bull. 2009, 32, 1177-1182.
42. Preuss, H. G., Echard, B., Yamashita, E., Perricone, N. V., High dose astaxanthin lowers blood pressure and increases insulin sensitivity in rats: are these effects interdependent? Inter. J. Med. Sci. 2011, 8, 126-138.
43. Le May, C., Pineau, T., Bigot, K., Kohl, C., et al., Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Lett. 2000, 475, 163-166.